RxDoctor Payments Data

Gregory Henson, MD

Family Medicine · Bentonville, ARNPI 1467715656

Payments from drug & device makers

$1,186in general payments, 2019–2025

Across 51 payments — averaging $23.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$386
  • Genentech USA, Inc.$121
  • Novo Nordisk$76
  • GSK$72
  • Astellas Pharma US Inc$66
  • Pfizer$63
  • plus $402 from 17 others

What the payments were for

  • Food & beverage$1,12094%
  • Education$666%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,186 in reported general payments places this provider in the 60th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$39,273
Medicare patients
94
Services billed
1,156

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide49$56,843
ZenpepLipase/Protease/Amylase16$52,840
EliquisApixaban48$41,902
JardianceEmpagliflozin27$25,222
LinzessLinaclotide20$15,585
OzempicSemaglutide15$13,876
FarxigaDapagliflozin Propanediol12$12,425
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$5,388
Breo ElliptaFluticasone/Vilanterol13$4,970
Gabapentin68$3,420
Varenicline Tartrate13$2,974
Sevelamer Carbonate11$1,758
Fentanyl13$1,620
Celecoxib37$1,542
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen68$1,411

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$43$56,84349 claims
PfizerEliquis$63$41,90248 claims
AbbVieLinzess$20$15,58520 claims
Novo NordiskOzempic$76$13,87615 claims
AstraZenecaFarxiga$386$12,42512 claims
GSKBreo Ellipta$72$4,97013 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Bentonville

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →